Healthcare Newsletter
Q2 2017

Reporting on services that support the life sciences including
COMMUNICATIONS | INFORMATION | MARKETING | MEDIA | TECHNOLOGY

DeSilva & Phillips is the premier advisor to healthcare service businesses that support the life sciences industry. Our clients include leaders in healthcare communications, information, marketing, media, and technology. We have served as an advisor on more than 40 healthcare deals with a combined value of more than $1.5 billion over our 20-year history. This quarterly newsletter is intended to provide you an overview of key transactions, trends and related news in the sector.

3 Health Care Trends That Don’t Hinge on the ACA

Whether Congress and the Trump administration succeed or fail in revising or repealing Obamacare in whole or in part, rich opportunities will exist for investors in healthcare because of three immutable trends, explain DeSilva + Phillips senior adviser Frank Baitman and Managing Director Ken Karpay in Harvard Business Review.

Deals, Investments

OVERVIEW: The U.S. healthcare M&A media and communications market ignored ongoing deliberations in Washington D.C. over whether to repeal, replace, revise or leave in place the Affordable Care Act, colloquially known as Obamacare. Any concern of uncertainty in the market was pushed aside, judged both by deals announced and by deals that remain in market and are expected to be announced by later this year. The active quarter was punctuated by Chicago-based Outcome Health’s announcement that it had raised $500 million in funds on a $5.5 billion valuation.

Details from the media over the past quarter:

Acquisition gives Teladoc an international footprint and significantly expands breadth of healthcare solutions

Teladoc to buy Best Doctors for $440M in cash and stock

Teladoc, Inc. (NYSE:TDOC), which claims to be the first and largest telehealth platform in the United States, plans to acquire Best Doctors, an expert medical consultation company. The acquisition is part of Teladoc’s plan to create a single solution for addressing a complete spectrum of medical conditions. The purchase price consists of $375 million cash and $65 million of Teladoc common stock. NASDAQ

Click to Read the Full Newsletter Here